Home Search

Epidyolex - search results

If you're not happy with the results, please do another search
Brexit and medicinal cannabis in the UK

Brexit’s Medical Cannabis Sting For UK Paediatric Patients

The UK’s Brexit transition period ends on 1 January 2021, and with it access to medical cannabis prescriptions filled in the EU. From January 1,...
GW Pharmaceuticals - Epidyolex in Australia

Australia’s TGA Approves Cannabidiol (CBD) Medicine

GW Pharmaceuticals announced last week the Australian Therapeutic Goods Administration (TGA) has approved its cannabidiol medicine Epidyolex for the treatment of seizures associated with...
CBD medication approved for tuberous sclerosis complex

CBD Medicine Approved For TSC Treatment In The USA

GW Pharmaceuticals has achieved one of its goals for this year - seeing Epidiolex approved for the treatment of seizures associated with tuberous sclerosis...
GW Pharmaceuticals Epidyolex

Cannabidiol Medicine Downscheduled In The UK

GW Pharmaceuticals' Epidyolex has been rescheduled in the UK, making life easier for patients, healthcare professionals and pharmacists. Epidyolex, which is marketed as Epidiolex in...
Epidiolex descheduled

Cannabidiol-Based Medicine Descheduled In The USA

GW Pharmaceuticals announced yesterday the United States Drug Enforcement Administration (DEA) has determined Epidiolex is no longer subject to the Controlled Substances Act (CSA),...
GW Pharmaceuticals - Epidiolex

GW Pharmaceuticals Turning Big Bucks From CBD

GW Pharmaceuticals (Nasdaq:GWPH) has posted better than expected results on the back of its cannabidiol-based medication Epidiolex. The company expects its total net product sales...
Cannabis polling - UK

Poll Results:  Use Of Street Cannabis Medicinally In The UK

A new poll reveals 2.8% of the British adult population is using "street cannabis" for medicinal purposes - up to 1.4 million people. A survey...
Advertisement
Hemp Seed